Nanoparticles to Cross Biological Barriers - Biomaterials Science: An Integrated Clinical and Engineering Approach - page 109

2. F. Alexis, J. Rhee, J.P. Richie, A.F. Radovic-Moreno, R. Langer, O.C. Farokhzad,
New frontiers in nanotechnology for cancer treatment, Urologic Oncology:
Seminars and Original Investigations 26 (2008) 74-85.
3. M. Sprintz, Editorial: Nanotechnology for advanced therapy and diagnosis,
Biomed. Microdevices 6 (2004) 101-103.
4. X. Wang, L. Yang, Z., Chen, D.M. Shin, Application of nanotechnology in cancer
therapy and imaging, CA: A Cancer Journal for Clinicians 58 (2008) 97-110.
5. S.S. Davis, Biomedical applications of nanotechnology: Implications for drug
targeting and gene therapy, Trends Biotechnol. 15 (1997) 217-224.
6. O.C. Farokhzad, Nanotechnology for drug delivery: The perfect partnership,
Expert Opinion on Drug Delivery 5 (2008) 927-929.
7. F. Alexis, E. Pridgen, L.K. Molnar, O.C. Farokhzad, Factors affecting the clear-
ance and biodistribution of polymeric nanoparticles, Molecular Pharmaceutics
5 (2008) 505-515.
8. D. Peer, J.M. Karp, S. Hong, O.C. Farokhzad, R. Margalit, R. Langer, Nanocarriers
as an emerging platform for cancer therapy, Nat Nano 2 (2007) 751-760.
9. M.E. Davis, Z. Chen, D.M. Shin, Nanoparticle therapeutics: An emerging treat-
ment modality for cancer, Nat Rev Drug Discov 7 (2008) 771-782.
10. R. Paull, J. Wolfe, P. Hebert, M. Sinkula, Investing in nanotechnology, Nat Biotech
21 (2003) 1144-1147.
11. H. Devalapally, A. Chakilam, M.M. Amiji, Role of nanotechnology in phar-
maceutical product development, Journal of Pharmaceutical Sciences 96 (2007)
2547-2565.
12. A. Sparreboom, C.D. Scripture, V. Trieu, P.J. Williams, T. De, A. Yang, B. Beals,
W.D. Figg, M. Hawkins, N. Desai, Comparative preclinical and clinical phar-
macokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel
(ABI-007) and paclitaxel formulated in cremophor (Taxol), Clinical Cancer
Research 11 (2005) 4136-4143.
13. W. Beecken, A. Fernandez, D. Panigrahy, E. Achilles, O. Kisker, E. Flynn,
M.J. Antonia, J. Folkman, Y. Shing, Efficacy of antiangiogenic therapy with
TNP-470 in superficial and invasive bladder cancer models in mice, Urology 56
(2000) 521-526.
14. T. Tanaka, H. Konno, I. Matsuda, S. Nakamura, S. Baba, Prevention of hepatic
metastasis of human colon cancer by angiogenesis inhibitor TNP-470, Cancer
Research 55 (1995) 836-839.
15. A.P. Kudelka, C.F. Verschraegen, E. Loyer, Complete remission of metastatic cer-
vical cancer with the angiogenesis inhibitor TNP-470, N. Engl. J. Med. 338 (1998)
991-992.
16. R. Satchi-Fainaro, M. Puder, J.W. Davies, H.T. Tran, D.A. Sampson, A.K. Greene,
G. Corfas, J. Folkman, Targeting angiogenesis with a conjugate of HPMA copo-
lymer and TNP-470, Nat. Med. 10 (2004) 255-261.
17. R. Satchi-Fainaro, R. Mamluk, L. Wang, S.M. Short, J.A. Nagy, D. Feng,
A.M. Dvorak, H.F. Dvorak, M. Puder, D. Mukhopadhyay, J. Folkman, Inhibition
of vessel permeability by TNP-470 and its polymer conjugate, caplostatin,
Cancer Cell 7 (2005) 251-261.
18. M.C. Garnett, Targeted drug conjugates: Principles and progress, Adv. Drug
Deliv. Rev. 53 (2001) 171-216.
19. C. Li, Poly(glutamic acid)-anticancer drug conjugates, Adv. Drug Deliv. Rev .
54 (2002) 695-713.